Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC) Meeting Abstract
| Authors: | Datko, F. M.; D'Andrea, G.; Dickler, M. N.; Theodoulou, M.; Goldfarb, S. B.; Lake, D.; Fornier, M. N.; Modi, S.; Sklarin, N. T.; Comen, E. A.; Fasano, J.; Gajria, D.; Drullinsky, P.; Murphy, C. G.; Syldor, A.; Patil, S.; Liu, J.; Chandarlapaty, S.; Hudis, C.; Dang, C. T. |
| Abstract Title: | Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC) |
| Meeting Title: | 2012 Breast Cancer Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 30 |
| Issue: | 27 Suppl. |
| Meeting Dates: | 2012 Sept 13-15 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2012-09-20 |
| Language: | English |
| ACCESSION: | WOS:000208892500131 |
| DOI: | 10.1200/jco.2012.30.27_suppl.134 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 134 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
